MedTrace Logo

Assessing Short-term Treatment Satisfaction and Quality of Life in Patients With Hidradenitis Suppurativa Initiated on Secukinumab.

NCT06785675 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 48

Last updated 2026-04-01

No results posted yet for this study

Summary

This study will be conducted to address the lack of concrete data on the impact of pharmaceutical intervention on short-term patient satisfaction and quality of life (QoL) in patients with Hidradenitis Suppurativa (HS) in real-world settings, especially in the Gulf Region.

Conditions

Interventions

OTHER

Secukinumab

This is an observational study. There is no treatment allocation.

Sponsors & Collaborators

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-10
Primary Completion
2026-09-30
Completion
2026-09-30

Countries

  • United Arab Emirates

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06785675 on ClinicalTrials.gov